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Abstract 
Objectives: This international, 12-week, double-blind, randomised, controlled trial 
assessed the efficacy and safety of indapamide sustained release (SR)/amlodipine 
single-pill combination (SPC) in mild-to-moderate hypertensive patients. 
Methods: Following a 4-week run-in period on amlodipine 5 mg, patients (SBP 150-
180 mmHg and/or DBP< 110 mmHg) were randomized to indapamide 1.5 mg 
SR/amlodipine 5 mg (IndSR/Aml) SPC or amlodipine 5 mg/valsartan 80 mg (Aml/Val) 
SPC with conditional up-titration at week 6. Office BP was assessed at baseline, weeks 
6 and 12; ambulatory and home blood pressure monitoring (ABPM / HBPM) at baseline 
and week 12.  
Results: Baseline characteristics were similar in both groups (57 years, 51% men, BP 
160/92 mmHg). 233 patients were randomized to IndSR/Aml and 232 to Aml/Val, of 
whom 48% and 57% were up-titrated, respectively. After 12 weeks, office SBP/DBP 
decreased similarly with both treatments (-21/-8 vs -20/-8 mmHg) leading to BP control 
in 50% and BP response in 70% of patients. Up-titration was effective (P<0.001) with 
both regimens, in favour of IndSR/Aml (SBP/DBP -12/-6 vs -7/-3 mmHg, respectively). 
ABPM (n=273) and HBPM (n=194) confirmed 24-hour efficacy of both regimens. In the 
subgroup of patients with sustained uncontrolled hypertension assessed by ABPM 
(n=216), office SBP/DBP decreased by -23/-13 vs  
-18/-10 mmHg, respectively (P=0.016/P=0.135, post-hoc analysis). Both treatments 
were generally well tolerated. 
Conclusion: Both regimens produced effective BP reductions confirmed by 
ABPM/HBPM. Both treatments were well tolerated, in accordance with the individual 
agents’ safety profile. 
Trial registration number: EUDRA CT n° 2012-001690-84 
Word count: 234 words (word limit: 250) 
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Condensed abstract 
Patients (n= 473) with mild-to-moderate uncontrolled essential hypertension treated 
with amlodipine were randomized to single-pill combination indapamide SR/amlodipine 
or amlodipine/valsartan regimens for 12 weeks, including up-titration at week 6 for 
those with uncontrolled blood pressure (BP). Both treatment regimens led to significant 
office BP reductions (BP control 50%, BP response 70%), with indapamide 
SR/amlodipine being more effective in decreasing systolic BP in case of sustained 
uncontrolled hypertension (post-hoc analysis). 24-hour ambulatory and home blood 
pressure monitoring results confirmed efficacy. Both treatment regimens were well 
tolerated in line with their known safety profile. 
 Word count: 92 words (word limit: 100) 
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Introduction  
Hypertension (HT) is a major public health problem  [1] with an estimated prevalence of 
20-24% worldwide [2]. Despite the wide range of available antihypertensive 
medications, blood pressure (BP) control rates remain particularly low, irrespective of 
world region, with only one third of treated patients being controlled to a BP <140/90 
mmHg [3,4]. As many patients having started treatment with a single agent will 
subsequently require ≥2 drugs from different pharmacological classes to reach their BP 
goals [4,5], the most recent 2018 European guidelines [6] recommend starting with a 
combination in most patients and preferably with a single-pill combination (SPC).  
Simplification of HT treatment by using SPCs has received increasing support from 
most guidelines over the last few years [5–16]. SPCs can simplify the task of adjusting 
and titrating the doses of their components and improve adherence [17–19]. Moreover, 
patients on SPC experienced a lower 5-year rate of cardiovascular events than those 
on free combinations [20].  
Diuretics and calcium channel blockers (CCB) are 2 major antihypertensive drug 
classes recommended for first line treatment, particularly for hypertensive patients with 
diabetes, the elderly, patients of African origin, patients with a history of stroke, isolated 
systolic hypertension or resistant hypertension [6,7,9,12,21,22]. Their combination is 
one of the recommended options with confirmed efficacy [5,7–9,12] in terms of BP 
reduction and clinical outcomes, but remains underused in clinical practice. A meta-
analysis of four long-term randomized clinical trials assessing such a combination in a 
total of 30,791 patients [23], mostly driven by the VALUE and FEVER studies [24,25] 
showed significant risk reduction for myocardial infarction (RR, 0.83; CI, 0.73–0.95) 
and stroke (RR, 0.77; CI, 0.64–0.92) compared with other combinations, while total and 
cardiovascular mortality were both reduced by 11% (RR, 0.89; 95% CI, 0.75–1.06 and 
0.89; CI, 0.71–1.10, respectively).  
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At the drug level, indapamide, a thiazide-like diuretic [26–29], and amlodipine 
[24,30,31], the most commonly used dihydropyridine CCB, have both demonstrated 
beneficial effects on cardiovascular and stroke outcomes in hypertensive patients. 
Indapamide SR/amlodipine is the first available SPC combining a thiazide diuretic with 
a dihydropyridine CCB, since 2013, and has been shown to be effective and well-
tolerated in a real-world setting study [32]. Herein we report the results of a Phase 3 
randomized clinical trial that assessed the blood pressure-lowering efficacy and 
tolerability of the 2 dosages of the SPC of indapamide SR / amlodipine with a step 
escalating dose strategy versus amlodipine/valsartan (dihydropyridine and angiotensin 
receptor blocker), a standard SPC commonly prescribed for hypertensive patients. 
 
Methods 
Patients 
Eligible patients were men or women aged over 18 years with mild-to-moderate 
uncontrolled essential hypertension, defined as SBP at least 150 and less than 180 
mmHg with DBP less than 110 mmHg (isolated systolic hypertension accepted). 
Patients were either not being treated or were not controlled by antihypertensive 
monotherapy and required a change of antihypertensive medication, without any 
exclusion criteria regarding the type of drug and duration of hypertension.  
 
The main exclusion criteria were a body mass index (BMI) > 32 kg/m²; diabetes; 
significant cardiovascular, cerebrovascular, hepatic or renal disorders; secondary 
hypertension; electrolytes abnormalities (hyper or hyponatremia, hyper or 
hypokaliemia, hyperuricemia); and any contra-indications or hypersensitivity to 
treatment with indapamide and/or amlodipine. 
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Study design 
Main study protocol 
This was a randomized, double-blind, double dummy, multicenter, 12-week, parallel 
group, phase III trial conducted in 13 countries [Supplemental file 1: Table S1]. 
The study was conducted in compliance with the current revision of the Declaration of 
Helsinki in accordance with Good Clinical Practice (GCP) guidelines. The study 
protocol was approved by local study centers’ institutional review boards or ethic 
committees. For all patients, the investigator proposed the participation in the 
Ambulatory Blood Pressure Monitoring and the Home Blood Pressure Monitoring 
protocols, considering few non selection criteria mainly related to anticipated difficulties 
to tolerate the device or to obtain valid out-of office measurements. All patients 
provided written informed consent before selection. The trial is registered at the 
European Union Clinical Trials Database (EUDRA CT n° 2012-001690-84).  
 
All selected uncontrolled hypertensive patients entered a 4-week run-in period, stopped 
their previous medication if any and were given amlodipine 5 mg open-label as one 
capsule daily in the morning. Those with remaining high BP (SBP ≥ 150 and <180 
mmHg and DBP <110 mmHg) at the end of this period were randomized to receive 
treatment of similar appearance for 12 weeks constituted by a SPC either of 
indapamide 1.5 mg SR /amlodipine 5 mg (IndSR/Aml) or amlodipine 5 mg/valsartan 80 
mg (Aml/Val) with the use of a placebo miming the comparative drug. Three visits were 
performed: at baseline (visit 1), week 6 (visit 2) and week 12 (visit 3). Patients with 
uncontrolled BP (office SBP ≥140 or DBP ≥ 90 mmHg) were up-titrated to the next 
dose i.e., IndSR/Aml 1.5/10 mg or Aml/Val 5/160 mg at visit 2 (W6). Use of other 
antihypertensive drugs or of drugs affecting BP was prohibited during the trial. 
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The main criteria for efficacy were office BP changes at week 12, with supine SBP 
being the primary criterion. Secondary criteria included supine DBP, rates of BP control 
(SBP/DBP < 140/90 mmHg) or response to treatment (controlled BP or 20 mmHg 
decrease in SBP or 10 mmHg decrease in DBP).  
 
Regarding safety assessment, patients were examined for orthostatic hypotension, vital 
signs and adverse events, recorded at all visits. Complete clinical laboratory 
examinations (biochemistry and haematology) and 12-lead electrocardiogram were 
performed at inclusion and at study end. Simplified laboratory tests (mainly sodium, 
potassium, uric acid, creatinine plasma measurements) were performed before the 
week-6 visit. 
 
Office BP assessment 
At each visit, office BP was measured at the same period of the day and recorded 3 
times at 1 min intervals in supine position, after 10 min of rest, using a validated digital 
BP device with an appropriate cuff size and a thermal printer (OMRON® model 705CP-
II, Omron Healthcare, Kyoto Japan). Office SBP and DBP were measured in a quiet 
room, at trough of study drug (i.e. 24 ± 3 hours after study drug intake). The mean of 
the last 2 values of the 3 measurements was considered for assessment. After the third 
measurement, patients were asked to stand up for an additional 1 min and 3-min BP 
measurements taken in a standing position.  
 
Out-of office BP measurement  
Out-of-office BP assessment was performed in 2 subgroups of patients on 24-h ABPM 
(ambulatory blood pressure monitoring) and HBPM (home blood pressure monitoring) 
parameters. ABPM and HBPM were performed using validated devices in agreement 
with current guidelines [33,34]. 
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ABPM and HBPM were always set-up before drug intake. All patients were trained by 
the investigator to use the HBPM device (same model for all the patients), to fill in the 
diary and to follow the standard procedure.  
ABPM over 24 hours was performed at baseline and week 12 using the Mobil-O-
Graph® (Stolberg, Germany) 24h PWA device on the same arm, with appropriate cuff. 
The measures were taken every 20 minutes. For the validation of an ABPM recording, 
a minimum duration of 23:20 hours and a minimum of 46 BP readings during the 24-
hour period were necessary. The earliest “Beginning of test” started at 7 a.m (the latest 
at 11 a.m), and ended the next day, just before the study drug intake. ABPM validation 
was done on-line by a study-specific software e-CoreLab®. Mean daytime (7:00 to 
22:00), night-time (22:00-7:00) and 24-h blood pressure values were calculated for 
each treatment period. 
 
The HBPM measurements were performed before each visit (baseline, week 6 and 
week 12), twice a day, on the same arm and at the same time every day, in the 
morning (between 6 a.m. and 10 a.m), before taking the study drug and in the evening 
(between 18:00 and 22:00, before dinner). A set of 3 seated BP measurements were 
automatically taken with a 1 minute interval 3 days before the visit and at the day of the 
office visit using an FOR A D40 (St. Gallen, Suisse)® device. Data were centralized, 
transferred to the e-CoreLab® and validated technically. Mean morning, evening and 
24-h blood pressure values over the 3 complete days preceding the visit were 
calculated for each treatment period. 
 
Statistical methods 
Efficacy analyses were performed according to the ITT principle: all patients 
randomized to treatment who received at least one dose of assigned treatment and 
who had at least one baseline and one post-baseline office SBP value. DBP was 
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assessed in the whole population but also in the 2 subgroups of patients with systolic 
and diastolic hypertension and with isolated systolic hypertension. The same applied 
for the ABPM and HBPM sub-studies. 
 
BP and heart rate (HR) changes were assessed using an analysis of covariance 
(ANCOVA) model adjusted for treatment, baseline and center (fixed effects), and 
control and response rates using Chi square tests for the comparison of the 2 
treatment regimens. Compliance with treatment was assessed by pill counts, by 
calculating the ratio between the number of study drugs considered as taken 
(calculated by subtracting the number of pills returned to clinic from the number of pills 
dispensed) and their theoretical numbers required during the study for a given patient. 
Safety was described in all patients who had taken at least one dose of study drug. 
 
The sample size of 224 patients per group was calculated to detect a difference of 3 
mmHg in the change from baseline in office SBP between the 2 treatment groups with 
a 80% power and a 2-sided significance level of 5%, assuming an SD of 11 mm Hg for 
each treatment group and a dropout rate of 5% after randomization. Non inferiority of 
indapamide/amlodipine over amlodipine/valsartan was tested with a margin of 3 mmHg 
for SBP and 2 mmHg for DBP at the 1-sided significance level of 2.5% (post-hoc 
analysis). P value associated with General Linear Model was provided.  
All statistical analyses were performed using SAS/PC Software version 9.2. 
 
Results  
Demography and baseline characteristics 
A total of 473 patients were randomly allocated to the two combination regimens, 
equally distributed across the 2 groups and well matched for baseline characteristics. 
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The ITT population included 233 patients allocated to indapamide SR/amlodipine and 
232 patients allocated to amlodipine/valsartan. The 12-week treatment period was 
completed by 94% of the patients (220 vs 223 patients, respectively). Out of the 30 
(6%) patients who withdrew from the study, three patients withdrew due to adverse 
events in the indapamide SR/amlodipine group and one patient withdrew due to lack of 
efficacy in the amlodipine/valsartan group. Protocol deviation (n= 7 in each group) and 
non-medical reasons (7 and 5 patients in the IndSR/Aml and Aml/Val group, 
respectively) completed the reasons for withdrawal. No patients were lost to follow-up. 
The use of titration at week 6 benefited slightly more the amlodipine/valsartan group, 
with 59% of the patients receiving the next dose as compared to indapamide 
SR/amlodipine (50%). Pill count results were similar between the two groups: 
99.0±3.3% vs 98.6±4.7% for IndSR/Aml and Aml/Val, respectively. 
 
ABPM and HBPM efficacy subsets were similarly distributed across treatment 
regimens. ABPM comprised 273 patients (133 versus 140 patients in the IndSR/Aml 
and Aml/Val groups, respectively) of whom 216 (79%) had sustained uncontrolled 
hypertension (SUCH) correctly distributed across the 2 treatment groups (104 and 112 
patients, respectively). SUCH is defined as an abnormal ABPM at baseline (mean 24h 
ASBP ≥ 130 mmHg and/or mean 24h ADBP ≥ 80 mmHg) excluding white coat 
uncontrolled hypertension (WUCH), defined by an elevated office BP but controlled 
ambulatory BP. HBPM comprised 194 patients distributed as 95 and 99 patients, 
respectively. 
Baseline demographic characteristics (51% men, 57 years old in average) showed no 
relevant between-group differences (Table 1). BMI was on average 26.8±2.5 kg/m², 
with only 8 patients above 30 kg/m². 41% of the patients presented with an isolated 
systolic hypertension (DBP <90 mmHg) and were well distributed across the 2 
treatment regimens. The majority of patients (71%) were on existing treatment for 
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hypertension at entry, mainly given as monotherapy (96%) represented by an agent 
acting on the renin-angiotensin system (50%), a calcium channel blocker (15%) or a 
diuretic (6%), well distributed across the 2 treatment regimens. Mean supine 
SBP/DBP at baseline was 160/92 mmHg after having received 5 mg of amlodipine for 
one month.  
Over the study period, compliance to treatment was excellent (98.8 ± 4.1%), with 
similar results by dose in both treatment regimens. 
 
Efficacy 
Office blood pressure parameters  
Overall, over 12 weeks, both treatment regimens significantly (p<0.001) decreased 
SBP and DBP by -21/-8 mmHg vs -20/-8 mmHg, in the indapamide SR/amlodipine and 
amlodipine/valsartan groups, respectively and showed equivalence between groups 
(Table 2). Pulse rate decreased slightly and similarly with both regimens, by -2.7 bpm 
and -0.7 bpm, respectively. In the subgroup of patients with isolated systolic 
hypertension, normal DBP at baseline remained preserved with both treatment 
regimens (by -2 mmHg, in both groups). At study end, 50% of the patients had their BP 
controlled (SBP<140/DBP<90 mmHg) and 70% responded to treatment, with both 
regimens.  
Patients with moderate hypertension benefited more from treatment with an office 
SBP/DBP decrease of -25/-11 mmHg versus -23/-10 mmHg with indapamide 
SR/amlodipine (n=124) and amlodipine/valsartan (n=127), respectively. 
When considering patients with sustained uncontrolled hypertension, the effect of 
indapamide SR/amlodipine on office SBP was found to be significantly superior (-4.7 
mmHg difference, P=0.016) to amlodipine/valsartan; with office SBP/DBP decreases of 
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-23/-10 mmHg vs -18/-8 mmHg, from 160/94 mmHg and 161/92 mmHg, respectively 
(supplemental file 2: Figure S2).  
 
Up-titration efficacy  
With the indapamide SR/amlodipine regimen, fewer patients were up-titrated (113 
(48%) versus 135 (58%) in the amlodipine/valsartan group). Uptitration was associated 
with further decreases in office BP with both treatment regimens (P<0.001 for each 
titration), favouring indapamide SR/amlodipine (-12/-6 mmHg versus -7/-3 mmHg for 
Aml/Val) (Table 3).  
 
ABPM and HBPM sub-studies  
ABPM was performed in 273 patients (133 in the IndSR/Aml group and 140 in the 
Aml/Val group), and confirmed the 24-hour efficacy of the 2 treatment regimens. Over 
24 hours, ambulatory SBP/DBP (ASBP/ASDBP) decreased by -7/-5 mmHg and -7/-4 
mmHg, respectively, reaching final ASBP/ADBP mean values of 128/80 mmHg and 
129/80 mmHg, respectively (Figure 1). Ambulatory heart rate (AHR) remained stable 
with the 2 regimens and decreased by -1.7 and -1.1 bpm, respectively. No relevant 
differences were observed regarding the different time periods studied reaching final 
mean ASBP/ADBP values of 131/83 mmHg and 132/84 mmHg for daytime period and 
123/74 mmHg and 123/75 mmHg for night-time period, respectively. Over these 
periods, AHR decreased by -1.6 and -1.1 bpm for daytime and -1.7 and -0.6 bpm for 
night-time, respectively. BP profiles over the 24-hour period at week 12 are shown in 
Figure 2.  
Similar findings were observed with home blood pressure monitoring, assessed in 194 
patients (95 in the IndSR/Aml group and 99 in the Aml/Val group). Home SBP/DBP 
decreased by -9/-5 mmHg in the indapamide SR/amlodipine group and by -8/-6 mmHg 
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in the amlodipine/valsartan group (Figure 3). Global, morning and evening periods 
provided similar profiles.  
 
Safety 
Treatment was generally well tolerated across the 2 groups, and no safety concerns 
were identified for any treatment dose. Overall, 3 patients (1.3%) in the indapamide 
SR/amlodipine group withdrew due to adverse events, all not serious and recovered 
(dizziness, asthenia and hypokalaemia). Overall, the rate of adverse events was 19.9% 
for the indapamide SR/amlodipine group (versus 11.9% for amlodipine/valsartan), 
mainly driven by the diuretic properties of indapamide: hypokalaemia (5.5% vs 0.8%, 
respectively), dizziness (2.1% vs 0%), hyperuricemia (1.3% vs 0%). Peripheral 
oedema, which is known to be amlodipine-dose dependent, occurred in few patients 
(1.3% vs 0.4%) and mainly with the 10mg dose of amlodipine. Orthostatic hypotension 
episodes were defined as BP decrease of 20mmHg for systolic and 10mmHg for 
diastolic pressure, respectively. These episodes were infrequent, only 3 in each group. 
Two patients in each group reported a serious adverse event: renal cancer and 
hypokalaemia for indapamide SR/amlodipine, and colon adenoma and myocardial 
ischemia for amlodipine/valsartan. Of note, 4 patients erroneously started treatment 
with double dose of indapamide SR/amlodipine 1.5/5 mg for up to 10 days without any 
symptoms. 
As expected with thiazides, there were few relevant changes in laboratory plasma 
values (Table 4). Mean changes were -0.2 ±0.5 and -0.0±0.4 mmol/L for potassium, -
0.1±2.6 and -0.4±2.3 mmol/L for sodium, -0.3±9.9 and 0.7±10.9 µmol/L for creatinine 
and 40.4±182.4 and -8.1±170.6 µmol/L for uric acid, in the indapamide SR/amlodipine 
and amlodipine/valsartan groups, respectively.  
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Discussion  
Efficacy on BP at office and out-of office measurements 
Our study showed that both dual regimens with indapamide SR/amlodipine or 
amlodipine/valsartan (respectively belonging to the thiazide-like diuretic/CCB or 
angiotensin receptor blocker(ARB)/CCB classes) were effective in lowering BP and 
were generally well tolerated in a population whose baseline characteristics were well 
distributed across the 2 treatment arms including pre-treatment drug classes.  
Interestingly, our study used the 3 main methods for accurately assessing BP-lowering 
efficacy, i.e. office (100% of the cohort) and out-of-office BP measurements in a large 
proportion using both ABPM (79% of the cohort) and/or HBPM (66% of the cohort). In 
that context, these last two measurements are a valuable supplement to office values 
[6,35,36] to overcome issues such as white-coat hypertension [5,6,10,37] and have 
been shown to be more predictive of cardiovascular risk than office BP [38–40]. 
 
Efficacy was observed with each of the 3 methods in the overall cohort, with similar 
profile in the non-Caucasians who represented 20% of the population (data not shown). 
Regarding the sub-groups of either isolated systolic hypertension (41%) or systolic and 
diastolic hypertension (59%), the patients were well distributed across the 2 treatment 
groups, and their changes in office DBP decreased similarly in both treatment groups  
(-2 mmHg for ISH and -12 mmHg for SDH).  
 
After controlling the comparability of the patients’ baseline characteristics between the 
whole population and those who underwent ABPM and HBPM, both of these methods 
corroborate and confirm the efficacy of the 2 treatments. In addition ABPM allowed the 
identification of a significant proportion of patients (21%) having white coat uncontrolled 
HT i.e. considered as not controlled at the office but controlled at ABPM after one 
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month of amlodipine monotherapy. With exclusion of these patients in post-hoc 
analyses we observed a difference between the two treatment regimens in favour of 
indapamide/amlodipine (while baseline values were found to be similar) in the sub-
group of sustained uncontrolled hypertension patients, which seems to be at higher 
cardiovascular risk [7,41–43]. This difference cannot be accounted for by a difference 
in treatment compliance, as both regimens were formulated as SPCs and pill count 
results were similar between the two groups. 
 
Method and design in line with the 2013 and 2018 European guidelines 
In line with usual practice and the 2013 ESH/ESC guidelines, office BP was measured 
in the presence of a healthcare professional, at trough (i.e., 24 hour after dosing) with a 
validated automatic device (Omron in supine position) with a BP target of <140/90 
mmHg. This remains the preferred method according to the 2018 European ESC/ESH 
guidelines [6].  
Regarding treatment options, the design of our study was drafted to be in line with the 
2013 ESH/ESC guidelines and current practice, which at the time of the protocol 
recommended to start treatment with monotherapy for most patients, followed by two-
drug therapy as the next step for patients with uncontrolled BP. Using a scheme with 
an active run-in period, we could verify the persistence of uncontrolled hypertension 
despite monotherapy with amlodipine 5 mg and to provide the same chance for both 
groups at inclusion. The combination of Indapamide/Amlodipine or 
Amlodipine/Valsartan was for both regimens the next logical step for these uncontrolled 
hypertensive patients (SBP/DBP: 150-180/<110 mmHg). The 12-week period provided 
sufficient study duration and allowed accurate evaluation of the BP-lowering efficacy 
with a conditional up-titration scheme at mid-course.  
 
Safety 
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Safety results for both regimens were in line with known safety profile of the individual 
agents and both regimens were generally well tolerated. Safety was mostly driven by 
the well-known thiazide properties of indapamide. Peripheral oedema, which is known 
to be related to CCB and which was reported to occur in 6% of patients over 12-week 
treatment [44], was uncommon in our study. It is recognized that ACEI or ARB 
combined with CCB reduce the risk [45], but we also observed a low occurrence with 
IndSR/Aml in our study, confirming previous results observed in the NESTOR study  
[46].  
 
In light of the strong recommendation of the latest 2018 ESC/ESH guidelines [6] to 
initiate treatment in most hypertensive patients with a combined therapy – preferably as 
SPC - indapamide SR/amlodipine represents an effective alternative to agents that 
inhibit the RAAS in patients with low-renin hypertension [47]. Black and elderly patient 
populations, who have a high incidence of low-renin hypertension, have also been 
shown to be the population that best respond to diuretics and CCBs [48]. Evidence 
from trials using amlodipine, indapamide or regimens based on either of these drugs 
have shown improvement in morbidity and mortality outcomes and target organ 
protection, as reviewed by Safar and Blacher [47]. 
 
Limitations 
Our study has some limitations. First, according to the study design assessing the 2 
dosage strengths available for indapamide SR/amlodipine (1.5/5 and 1.5/10mg) SPC, 
only 2 usual dosages of amlodipine/valsartan were tested. 
Second, considering the inclusion and exclusion criteria, the results reported herein are 
valid for the selected population, and were not evaluated in other populations at risk, 
for example in patients with diabetes. However, even though not evaluated in this 
study, data in diabetic patients including elderly patients have been previously reported 
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in the NESTOR-CCB analyses that showed the BP benefit of the combination over an 
ACE inhibitor and CCB combination [46,49]. 
Similarly, the study did not focus on low-renin hypertension patients, such as the black 
or the elderly, who would probably benefit more from the indapamide/amlodipine 
combination, as recently confirmed by the CREOLE study [50], specifically performed 
to assess the most efficient combination treatment classes including a CCB + diuretic, 
in the black sub-saharian population.  
 
Perspectives 
The use of SPC is highly recommended by most guidelines and emphasized by the 
recent 2018 ESC/ESH guidelines as we have evidence that it improves the rate of BP 
control in hypertensive patients. The indapamide SR/amlodipine combination is of 
particular interest for patients with low-renin hypertension – considered as relatively 
common, and is believed to affect up to 30% of patients with essential hypertension 
[51], especially in the black population, given that to our knowledge there is no other 
SPC of a thiazide diuretic and CCB marketed yet. 
 
Conclusion 
In patients with mild-to-moderate, essential hypertension, indapamide SR/amlodipine 
SPC was found to be at least equivalent to amlodipine/valsartan with regard to office 
BP reduction. Each dose was associated with significant decreases in office BP. At 
study end, 50% of patients had achieved BP control and 70% a response to treatment. 
Efficacy was confirmed by ABPM and HBPM measurements. The persisting 24-hour 
effect on BP is known to have a beneficial effect on cardiovascular risk reduction. No 
safety concern occurred in the study as the safety profile was mostly driven by the 
thiazide properties of indapamide. This is the first marketed SPC that includes a 
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thiazide diuretic and a calcium channel blocker and thus provides a new therapeutic 
opportunity for the treatment of hypertension. 
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Table 1: Baseline demographic characteristics in the randomized set  
 
Baseline characteristic (m±SD) IndSR/Aml 
(n=237) 
Aml/Val 
(n=236) 
Global 
(n=473) 
Age (years) 57 ± 11 57 ± 12 57 ± 11 
Men, n (%) 121 (51%) 120 (51%) 241 (51%) 
Caucasian, n (%) 189 (80%) 185 (78%) 374 (79%) 
Mean Office Supine SBP ± SD (mmHg) 160 ± 7 160 ± 7 160 ± 7 
Mean Office Supine DBP ± SD (mmHg) 92 ± 10 91 ± 10 92 ± 10 
Mean Heart Rate HR± SD (bpm) 76 ± 12 75 ± 12 75 ± 12 
Duration of hypertension (months), median 29 36 35 
Hypertension severity:    
Mild (%) 
Moderate (%) 
47.3 
52.7 
44.6 
55.4 
46.0 
54.0 
Previously treated , n (%) with : 
 Blockers of the Renin-Angiotensin System 
• ACE inhibitors 
• ARBs 
 Calcium Channel Blockers 
 Diuretics 
171 (72%) 
125 (53%) 
91 (38%) 
34 (14%) 
37 (16%) 
14 (6%) 
163 (69%) 
111 (47%) 
79 (34%) 
33 (14%) 
35 (15%) 
15 (6%) 
374 (71%) 
236 (50%) 
170 (36%) 
67 (14%) 
72 (15%) 
29 (6%) 
Hypercholesterolemia (%) 24.5 25.4 25.0 
Smoker (%) 12.7 15.3 14.0 
ACE: angiotensin-converting enzyme ; Aml/Val : Amlodipine/Valsartan ; ARBs: angiotensin receptor 
blockers ; bpm: beats per minute; DBP: diastolic blood pressure ; HR: heart rate; IndSR/Aml: indapamide 
SR/Amlodipine ; SBP: systolic blood pressure; SD: standard deviation 
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 Table 2: Office supine blood pressure parameters and heart rate: change from baseline in 
the whole population 
 
Office supine blood 
pressure – overall 
population (m±SD) 
Indapamide SR/Amlodipine  
N=233 
Amlodipine/Valsarta
n N=232 
Between group 
difference E [95%, CI], 
P value (non inferiority)  
SBP at baseline - Mean 
value (mmHg) 
160 ± 7 160 ± 7 
 
Change from baseline 
(mmHg) 
-21 ± 15*** -20 ± 16*** -1.1, [-3.7; 1.6], 
p=0.001 
DBP at baseline - Mean 
value (mmHg) 
92 ± 10 91 ± 10 
 
Change from baseline 
(mmHg) 
-8 ± 10*** -8 ± 11*** 0.2 [-1.4; 1.8], p=0.014 
Heart rate at baseline – 
Mean value (bpm) 
76±12 74±12  
Change from baseline 
(bpm) 
-2.7 ± 11 -0.7 ± 11.9 -0.6 [-2.4; 1.1] 
 
Change over 12-week. E, estimate of the between-group difference in adjusted mean changes from 
baseline using a general linear model with treatment, baseline and country as covariates, with 
associated 95% confidence intervals (CIs) and P non inferiority value with a limit margin of 3 mmHg for 
SBP and 2 mmHg for DBP. 
*** P within group <0.001 
Aml/Val : Amlodipine/Valsartan ; bpm: beats per minute; DBP: diastolic blood pressure; IndSR/Aml: 
indapamide SR/Amlodipine ; SBP: systolic blood pressure; SD: standard deviation 
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Table 3: Changes in office blood pressure (mean ± standard error) according to dose (up-
titration efficacy) in the whole cohort 
 Period Treatment dose n Office SBP Office DBP 
Step 1 W0-W6 IndSR/Aml  1.5/5 mg 233 -17±1*** -6±1*** 
 Aml/Val   5/80 mg 231 -16±1*** -7±1*** 
Step 2 W6-W12 IndSR/Aml  1.5/10 mg 113 -12±1*** -6±1*** 
 Aml/Val   5/160 mg 135 -7±1*** -3±1**** 
 ***, P<0.001 
Aml/Val : Amlodipine/Valsartan; DBP: diastolic blood pressure ; IndSR/Aml: indapamide SR/Amlodipine ; 
SBP: systolic blood pressure 
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Table 4: Changes in plasma metabolic and renal parameters – Mean changes over the period 
(Mean ± SD) 
  
Parameter (unit) Change from baseline 
 Indapamide SR/Amlodipine Amlodipine/Valsartan 
Sodium (mmol/L) -0.1±2.6 -0.4±2.3 
Potassium (mmol/L) -0.2±0.5 -0.0±0.4 
Creatinine (umol/L) -0.3±9.9 0.7±10.9 
Glucose (mmol/L) 0.2±1.5 0.1±1.6 
Triglycerides (mmol/L) -0.04±1.07 0.02±1.03 
Cholesterol (mmol/L) -0.04±1.08 -0.14±1.06 
HDL Cholesterol (mmol/L) -0.13±2.05 -0.53±3.17 
LDL Cholesterol (mmol/L) 0.02±2.56 -0.17±1.71 
Uric acid (µmol/L) 40.4±182.4 -8.1±170.6 
 
HDL: high-density lipoprotein; LDL: low-density lipoprotein  
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Figure 1. 12-week changes in ambulatory blood pressure monitoring parameters (whole 
cohort). Change from baseline in the ambulatory systolic blood pressure (ASBP), ambulatory 
diastolic blood pressure (ADBP) and ambulatory heart rate (AHR). 
 
 
ASBP and ADBP values are in mmHg; AHR values are in bpm. 
Aml/Val : Amlodipine/Valsartan; IndSR/Aml: indapamide SR/Amlodipine   
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Figure 2. 24-hour profile at week 12 with both treatment regimens  
 
Aml/Val : Amlodipine/Valsartan; IndSR/Aml: indapamide SR/Amlodipine   
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Figure 3. 12-week changes in Home blood pressure parameters (whole cohort). Change from 
baseline in Home systolic blood pressure (HSBP), Home diastolic blood pressure (HDBP) and 
Home heart rate (HHR) 
 
 
 
 
HSBP and HDBP values are in mmHg; HHR values are in bpm. 
 
Aml/Val : Amlodipine/Valsartan; IndSR/Aml: indapamide SR/Amlodipine 
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Supplemental Files 
Supplemental File 1: Table S1. Study characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Countries involved in the study : Argentina, Bulgaria, Hungary, Latvia, Lithuania, Mexico, 
Poland, Romania, Russian Federation, South Africa, Thailand, Ukraine, Vietnam.  
The investigators were hypertension specialists or general practitioners.  
Patients and investigators were blinded to the treatment allocation.  
Fixed Treatment randomization was balanced (ratio 1 to 1) and stratified by centre  
Treatment –regimens used the double dummy and were strictly of the same appearance to 
respect study blinding.  
Therapeutic units were supplied by Les Laboratoires Servier Industrie. 
Centralisation of the ABPM/HBPM data was performed by a web-based system (e-
CoreLab®, Paris, France) including an automatic test validation 
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Supplemental File 2: Figure S2. 12-week change in office supine blood pressure (SBP and 
DBP) in patients with sustained uncontrolled hypertension 
 
 
 
 
 
 
IndSR/Aml: indapamide SR/amlodipine (n=104) ; Aml/Val: amlodipine/valsartan (n=112) 
Difference between group: mean, 95%CI adjusted on baseline values and country 
*** P within group <0.001 
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